Abhimanyu Ghose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Abhimanyu Ghose has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Rekha Chaudhary
4 shared publicationsNamrata Sethi
2 shared publications- Zeeshan Tariq
Ruppert Health Center
2 shared publications Asma Taj
1 shared publicationBilal Saeed
1 shared publicationDavid Harmon
1 shared publication
Latest Publications
- 1 November 2013
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 20 (6) , e723-e725
Age Old Dapsone in the Treatment of Idiopathic Thrombocytopenic Purpura—A Case Report With Review
Idiopathic thrombocytopenic purpura (ITP) is characterized by premature platelet destruction in the reticuloendothelial system due to the presence of autoantibodies against the platelet membrane proteins. Patients who are resistant to the traditional treatment options that include the administration of steroids, IV immunoglobulin, and antirhesus D immunoglobulin and the performance of a splenectomy are diagnosed to have refractory chronic ITP. Management options in these patients are not well defined. Long-term steroids, rituximab, danazol, azathioprine, and cyclophosphamide have variable efficacy and at the same time carry significant side effects. We present the case of a patient treated effectively with dapsone, a drug that is much safer than other drugs and which can be used before resorting to splenectomy; we also include a review of the literature establishing its role in the management of ITP.
- 1 November 2013
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 20 (6) , e723-e725
Age Old Dapsone in the Treatment of Idiopathic Thrombocytopenic Purpura—A Case Report With Review
Idiopathic thrombocytopenic purpura (ITP) is characterized by premature platelet destruction in the reticuloendothelial system due to the presence of autoantibodies against the platelet membrane proteins. Patients who are resistant to the traditional treatment options that include the administration of steroids, IV immunoglobulin, and antirhesus D immunoglobulin and the performance of a splenectomy are diagnosed to have refractory chronic ITP. Management options in these patients are not well defined. Long-term steroids, rituximab, danazol, azathioprine, and cyclophosphamide have variable efficacy and at the same time carry significant side effects. We present the case of a patient treated effectively with dapsone, a drug that is much safer than other drugs and which can be used before resorting to splenectomy; we also include a review of the literature establishing its role in the management of ITP.
- 1 March 2012
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 19 (2) , e95-e97
A Case Report of Complete Remission of Pulmonary Metastases From Epithelioid Sarcoma to Navelbine Chemotherapy
Management of soft tissue sarcomas can be very challenging because they have a high rate of metastasis, especially to the lungs, and respond very poorly to the currently available chemotherapeutic drugs. We present a case of epithelioid sarcoma in which complete remission of pulmonary metastases was observed after treatment with a single agent, navelbine, a vinca alkaloid, and a potential therapeutic agent. The patient has been persistently free of metastases for 4 years since treatment with navelbine. Further studies are warranted to establish the role of navelbine for the treatment of soft tissue sarcoma and their metastases.
- 1 March 2012
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 19 (2) , e95-e97
A Case Report of Complete Remission of Pulmonary Metastases From Epithelioid Sarcoma to Navelbine Chemotherapy
Management of soft tissue sarcomas can be very challenging because they have a high rate of metastasis, especially to the lungs, and respond very poorly to the currently available chemotherapeutic drugs. We present a case of epithelioid sarcoma in which complete remission of pulmonary metastases was observed after treatment with a single agent, navelbine, a vinca alkaloid, and a potential therapeutic agent. The patient has been persistently free of metastases for 4 years since treatment with navelbine. Further studies are warranted to establish the role of navelbine for the treatment of soft tissue sarcoma and their metastases.
- 1 January 2012
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 19 (1) , e56-e58
Treatment of Multidrug Resistant Advanced Alveolar Soft Part Sarcoma With Sunitinib
Sunitinib is a tyrosine kinase/angiogenesis inhibitor with proven efficacy in gastrointestinal stromal tumor and advanced renal cell carcinoma. We are presenting the case report of a patient with aggressive alveolar soft part sarcoma with lung and bone metastases, who had failed multiple chemotherapy regimens showing significant response to sunitinib. There was not only complete regression of the primary tumor, stabilization of his bone metastases and significant improvement in the quality of life. Our report shows that sunitinib has the capability of playing a pivotal role in the management of non-gastrointestinal stromal tumors like alveolar soft part sarcoma. Further research and trials must be encouraged over the use of this drug as it is most definitely promising.
- 1 January 2012
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 19 (1) , e56-e58
Treatment of Multidrug Resistant Advanced Alveolar Soft Part Sarcoma With Sunitinib
Sunitinib is a tyrosine kinase/angiogenesis inhibitor with proven efficacy in gastrointestinal stromal tumor and advanced renal cell carcinoma. We are presenting the case report of a patient with aggressive alveolar soft part sarcoma with lung and bone metastases, who had failed multiple chemotherapy regimens showing significant response to sunitinib. There was not only complete regression of the primary tumor, stabilization of his bone metastases and significant improvement in the quality of life. Our report shows that sunitinib has the capability of playing a pivotal role in the management of non-gastrointestinal stromal tumors like alveolar soft part sarcoma. Further research and trials must be encouraged over the use of this drug as it is most definitely promising.
- 1 November 2011
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 18 (6) , e255-e257
Chemotherapy Versus Surgery in Primary B-Cell Lymphoma Masquerading as Klatskin Tumor—A Diagnostic and Therapeutic Dilemma
Primary lymphoma in the region of the liver bed mimicking hilar cholangiocarcinoma or Klatskin tumor is very rare. A patient presented with obstructive jaundice along with right upper quadrant pain, weight loss, and decreased appetite. Apart from altered liver function, her lactate dehydrogenase was significantly elevated, and imaging studies showed prominent lesion close to the liver bed with localized lymphadenopathy. The diagnosis ultimately reached at by biopsy and immunohistochemical staining was diffuse large B-cell lymphoma. Such cases are very infrequent, but demand awareness. The sooner the diagnosis can be reached by minimally invasive procedures, the earlier chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone can be initiated and laparotomy can be avoided as chemotherapy is the mainstay of treatment, even in the presence of jaundice.
- 1 November 2011
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 18 (6) , e255-e257
Chemotherapy Versus Surgery in Primary B-Cell Lymphoma Masquerading as Klatskin Tumor—A Diagnostic and Therapeutic Dilemma
Primary lymphoma in the region of the liver bed mimicking hilar cholangiocarcinoma or Klatskin tumor is very rare. A patient presented with obstructive jaundice along with right upper quadrant pain, weight loss, and decreased appetite. Apart from altered liver function, her lactate dehydrogenase was significantly elevated, and imaging studies showed prominent lesion close to the liver bed with localized lymphadenopathy. The diagnosis ultimately reached at by biopsy and immunohistochemical staining was diffuse large B-cell lymphoma. Such cases are very infrequent, but demand awareness. The sooner the diagnosis can be reached by minimally invasive procedures, the earlier chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone can be initiated and laparotomy can be avoided as chemotherapy is the mainstay of treatment, even in the presence of jaundice.
- 1 July 2011
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 18 (4) , e123-e125
Acute Dyspnea From Treatment of AL Amyloidisis With Bortezomib
Bortezomib with or without dexamethasone has been reported to be very effective and well tolerated in the treatment of AL amyloidosis. Commonly reported adverse effects are fatigue, nausea, vomiting, diarrhea, constipation, postural hypotension from autonomic neuropathy, peripheral neuropathy, thrombocytopenia and anemia. Dyspnea has been rarely reported as an adverse effect of bortezomib therapy in AL amyloidosis. We are reporting three case reports of patients suffering from AL amyloidodis, who had new onset acute dyspnea secondary to bortezomib treatment that required drug discontinuation. There might be some correlation between the AL amyloidosis disease and bortezomib associated dyspnea, but the pathophysiology is poorly understood.
- 1 July 2011
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 18 (4) , e123-e125
Acute Dyspnea From Treatment of AL Amyloidisis With Bortezomib
Bortezomib with or without dexamethasone has been reported to be very effective and well tolerated in the treatment of AL amyloidosis. Commonly reported adverse effects are fatigue, nausea, vomiting, diarrhea, constipation, postural hypotension from autonomic neuropathy, peripheral neuropathy, thrombocytopenia and anemia. Dyspnea has been rarely reported as an adverse effect of bortezomib therapy in AL amyloidosis. We are reporting three case reports of patients suffering from AL amyloidodis, who had new onset acute dyspnea secondary to bortezomib treatment that required drug discontinuation. There might be some correlation between the AL amyloidosis disease and bortezomib associated dyspnea, but the pathophysiology is poorly understood.
- 16 December 2010
- Published by Wiley in Hematological Oncology
- Vol. 30 (1) , 53-55
Bone marrow donation perceptions among healthcare workers: a survey at University of Toledo Medical Center
- 16 December 2010
- Published by Wiley in Hematological Oncology
- Vol. 30 (1) , 53-55
Bone marrow donation perceptions among healthcare workers: a survey at University of Toledo Medical Center